SUNLENCA® Has a Demonstrated Safety and Tolerability Profile Through Week 52 in the CAPELLA Clinical Trial^1-3

Adverse Reactions (All Grades) Reported in ≥3% of HTE Adults With HIV-1 Receiving SUNLENCA Through Week 52 (N=72)¹

• Injection site reactions reported in >1% of participants were swelling (36%), pain (31%), erythema (31%), nodule (25%), induration (15%), pruritus (6%), extravasation (3%), and mass (3%). Injection site reactions reported in 1% of participants included discomfort, hematoma, edema, and ulcer¹
  • The median time to resolution of all injection site reactions excluding nodules and indurations was 5 days^1,*
• Most injection site reactions were mild (Grade 1, 44%) or moderate (Grade 2, 17%)¹
  • Four percent of participants experienced a severe (Grade 3) injection site reaction (erythema, pain, swelling) that resolved within 15 days¹
• One participant discontinued SUNLENCA after the Week 52 injection due to an injection site nodule (Grade 1)^3,†
• Improper administration (intradermal injection) has been associated with serious injection site reactions¹

The range of all injection site reactions was 1 to 183 days. The median time to resolution of nodules and indurations was 148 (range: 41 to 727) and 70 (range: 3 to 252) days, respectively.¹ When reported, nodules and indurations were palpable but not visible and were approximately 1 to 4 cm in size. Qualitative descriptions were not routinely reported, nor were measurements routinely performed or standardized.¹